Alızada S., Samadzade U., Mammadov O., Caliskan C., Ozakbas S.
Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, ss.1774-1775, (Özet Bildiri)
-
Yayın Türü:
Bildiri / Özet Bildiri
-
Basıldığı Şehir:
Barcelona
-
Basıldığı Ülke:
İspanya
-
Sayfa Sayıları:
ss.1774-1775
-
Dokuz Eylül Üniversitesi Adresli:
Evet
Özet
Introduction: Fingolimod is a widely used oral disease-modifying therapy (DMT) for multiple sclerosis (MS), known for reducing relapse rates and delaying disease progression.
Objectives/Aims: This study aimed to assess the clinical impact of fingolimod by comparing disease activity and progression over three years before and after treatment initiation.
Methods: A retrospective analysis was conducted on 657 MS patients treated with fingolimod, including 596 with relapsing MS and 61 with secondary progressive MS. Key clinical measures, including Expanded Disability Status Scale (EDSS) scores, annualized relapse rate (ARR), and no evidence of disease activity (NEDA-3) status, were assessed at three time points: three years before fingolimod initiation, at treatment initiation, and three years post-treatment.
Results: Among relapsing MS patients (mean age 45.0 ± 10.2; 69.5% female), ARR significantly declined from 0.34 before treatment to 0.08 after three years of fingolimod therapy, while mean EDSS remained stable (1.48 pre-treatment, 1.48 at initiation, 1.43 post-treatment). Notably, 69.6% of patients achieved NEDA-3. Patients who attained NEDA-3 were older (45.64 vs. 43.55 years, p=0.021), had longer disease duration (5.84 vs. 5.09 years, p=0.005), and a lower baseline EDSS (1.22 vs. 2.07, p<0.001) compared to NEDA-3-negative individuals.
In secondary progressive MS patients (mean age 50.2 ± 10.9; 65.6% female), EDSS scores increased from 5.12 pre-treatment to 6.10 post-treatment over the six-year period, indicating ongoing disability progression. However, ARR decreased from 0.61 to 0.27. Only 16.4% of these patients achieved NEDA-3, and those who did had significantly higher baseline EDSS scores (6.11 vs. 4.94, p=0.002). No significant differences in age or disease duration were observed between NEDA-3-positive and NEDA-3-negative patients.
Conclusion: Fingolimod demonstrated strong efficacy in reducing relapse rates and maintaining overall clinical stability in relapsing MS patients, with a substantial proportion achieving NEDA-3. In secondary progressive MS, while ARR declined, disability progression remained evident, underscoring the need for more effective treatment options for this patient subgroup. These findings reinforce fingolimod’s long-term disease-modifying effects in relapsing MS and provide valuable insights into patient characteristics associated with better treatment outcomes.
Disclosure of interest: Said Alizada: nothing to disclose. Ulvi Samadzade: nothing to disclose. Can Caliskan: nothing to disclose. Orkhan Mammadov: nothing to disclose. Serkan Ozakbas: nothing to disclose.